RAND:EURONEXT AMSTERDAMRandstad NV Analysis
Data as of 2026-07-31 - not real-time
$10.01
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
Rand Capital’s shares are currently trading below both short‑term and intermediate moving averages, and the RSI sits in the low‑40s, indicating limited upside momentum. The MACD has just turned marginally bullish, but the price remains near a key support level, suggesting a fragile technical backdrop.
The company offers a double‑digit dividend yield with a payout ratio around half of earnings, yet it reports negative earnings and a modest free‑cash‑flow profile, raising questions about dividend sustainability. Low beta points to limited market‑wide correlation, but the stock’s high 30‑day volatility and a historical drawdown near half of its peak underscore significant price risk, compounded by thin trading volumes that heighten liquidity concerns.
The company offers a double‑digit dividend yield with a payout ratio around half of earnings, yet it reports negative earnings and a modest free‑cash‑flow profile, raising questions about dividend sustainability. Low beta points to limited market‑wide correlation, but the stock’s high 30‑day volatility and a historical drawdown near half of its peak underscore significant price risk, compounded by thin trading volumes that heighten liquidity concerns.
Market Outlook
Short Term
< 1 yearCautious
Model confidence: 7/10
Key Factors
- Price below key moving averages and near support
- Technical indicators mixed with limited momentum
- High dividend yield may be unsustainable given negative earnings
Medium Term
1–3 yearsNeutral
Model confidence: 5/10
Key Factors
- Potential income appeal from dividend if cash flow holds
- Valuation still appears stretched relative to DCF
- Persistent volatility and liquidity constraints
Long Term
> 3 yearsNeutral
Model confidence: 4/10
Key Factors
- Fundamental weakness with negative profitability
- Asset‑management sector exposure to broader market cycles
- Low beta suggests limited systematic risk but high idiosyncratic risk
Key Metrics & Analysis
Financial Health
Revenue Growth-38.30%
Profit Margin-162.06%
ROE-15.91%
ROA4.96%
Debt/Equity0.98
P/B Ratio0.6
Op. Cash Flow$5.1K
Free Cash Flow$1.6M
Industry P/E18.0
Technical Analysis
TrendBearish
RSI41.8
Support$10.00
Resistance$10.35
MA 20$10.12
MA 50$10.32
MA 200$11.76
MACDBullish
VolumeIncreasing
Fear & Greed Index92.88
Valuation
Fair Value$6.64
GradeOvervalued
TypeValue
Dividend Yield11.59%
Risk Assessment
Beta0.21
Volatility18.00%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskMedium
Liquidity RiskHigh
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.